HHS Secretary Alex Azar, formerly the president for the U.S. division of Eli Lilly, has sought to deliver drug pricing wins that President Trump can tout on the campaign trail. In May, Azar called the rule “the single most significant step any administration has taken toward a simple commitment: American patients deserve to know the prices of the health care they receive.”
Slated to go into effect Tuesday, the rule would have required drugmakers to include the list price of their medications if they cost $35 or more for a month’s supply, or for the usual course of therapy.
HHS spokeswoman Caitlin Oakley said the administration is “disappointed in the court’s decision and will be working with the Department of Justice on next steps related to the litigation.”
Judge Amit P. Mehta of the U.S. District Court for the District of Columbia said the court did not question HHS’s motives or take a view on whether drugmakers should have to disclose their prices.
“That policy very well could be an effective tool in halting the rising cost of prescription drugs,” Mehta wrote. “But no matter how vexing the problem of spiraling drug costs may be, HHS cannot do more than what Congress has authorized.”
The judge did not rule on the drug companies’ contention that the rule was “compelled speech” that would have violated their First Amendment rights.
Drug companies have argued that list prices do not reflect what most patients pay for prescription medicines because they do not account for the discounts negotiated by insurers. Some health-care analysts are also skeptical that providing the information would have any effect on consumers’ behavior.
But patient advocacy groups have said that Americans should know how much they could pay for medications, and that drug companies should be forced to disclose just how much they are charging.
“Drug list prices have been shrouded in secrecy for too long,” AARP Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond said in a statement on Monday. “Today’s ruling is a step backward in the battle against skyrocketing drug prices and providing more information to consumers. Americans should be trusted to evaluate drug price information and discuss any concerns with their health care providers.”
President Trump made lowering drug prices a central issue of his 2016 presidential campaign and has pressured advisers to deliver talking points ahead of the 2020 campaign, where he is hoping to make health care and drug costs a top issue. The television ad rule was outlined in a drug pricing blueprint Trump and Azar rolled out last year at the White House with great fanfare.